Boehringer kicks back unwanted Amylin analog drug work to Zealand Pharma

Boehringer
Boehringer Ingelheim's decision to kick back a program to Zealand Pharma comes six years after the pair also reset a similar diabetes pact. (Boehringer Ingelheim)

German pharma Boehringer Ingelheim has decided it will no longer work on Zealand Pharma’s experimental diabetes therapy, leaving the biotech to think about next steps for the program.

The Danish biotech said it has been handed back the rights to an Amylin analog program from partner Boehringer, including “a once-weekly lead molecule.”

The original pact dates all the way back to 2014 and, incidentally, came after a reset and rethink of an older pact when the pair agreed to start over to develop a GLP-1 diabetes drug after they decided to part ways on a lead program.

Sponsored by BHE

[Webinar] State of Data Analytics and Machine Learning in the Life Sciences Industry: 2020 Benchmarking Survey

Thursday, June 25, 2020 | 2:00pm ET | 11:00am PT

Join us Thursday, June 25th for a look at the current state of analytics in the life sciences industry. We will present the results from our industry survey with FiercePharma on how 100 of your peers are leveraging data analytics to respond to today’s challenges and generate timely, high value insights.

Here, ZP2929, a once-a-day glucagon/GLP-1 dual agonist, was axed, with a new focus found. You can now add the Amylin program to that list of unwanted meds.

But not all ties have been cut: Boehringer will still be working on the once-weekly GLP-1/glucagon analog known as BI 456906, which has also been licensed from Zealand and is set for midstage testing.

Given its partner’s lack of zeal, Zealand Pharma will “decide on the next development steps for the Amylin analog program following a detailed evaluation,” it said in a statement. The pair gave no details as to why the pharma has axed work on the program. 

“We have been collaborating with Boehringer Ingelheim on two candidates, both of which are potential treatments for obesity and Type 2 diabetes. We respect Boehringer’s decision to focus development on the GLP-1/glucagon asset, which will advance into Phase 2 development,” said Emmanuel Dulac, president and CEO at Zealand Pharma.

“We now regain the worldwide rights to the Amylin analog program, and are evaluating its development path within our pipeline. We are confident in the continued strong partnership with Boehringer Ingelheim and look forward to advancing the GLP-1/glucagon product with them.”

Suggested Articles

Singapore is planning to outfit each of its 5.7 million residents with a simple wearable device to track people who have been exposed to COVID-19.

The agency delivered its first batch of antibody test results in May, covering a dozen products independently evaluated by the NIH and CDC.

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.